Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $59.11

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been assigned an average rating of "Buy" from the nineteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $59.11.

A number of equities research analysts have recently issued reports on KYMR shares. UBS Group lowered their target price on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. BTIG Research restated a "buy" rating and set a $59.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Guggenheim restated a "buy" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, June 3rd. Wells Fargo & Company lowered their price objective on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, June 26th. Finally, B. Riley upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the company from $38.00 to $60.00 in a research note on Tuesday, June 3rd.

Kymera Therapeutics Stock Performance

NASDAQ KYMR traded up $0.84 during trading hours on Thursday, hitting $46.35. 421,302 shares of the company's stock were exchanged, compared to its average volume of 618,161. The business's 50 day moving average is $40.35 and its 200-day moving average is $36.15. Kymera Therapeutics has a 12-month low of $19.45 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The company's quarterly revenue was up 114.6% compared to the same quarter last year. During the same period last year, the business posted ($0.69) EPS. On average, research analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bros. Advisors Lp Baker acquired 655,500 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The stock was acquired at an average price of $44.00 per share, for a total transaction of $28,842,000.00. Following the transaction, the director directly owned 6,117,295 shares of the company's stock, valued at $269,160,980. This trade represents a 12.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey W. Albers sold 6,349 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $311,101.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 48,349 shares of company stock worth $2,334,301. 16.01% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KYMR. Northern Trust Corp raised its stake in Kymera Therapeutics by 14.0% during the 4th quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after acquiring an additional 53,658 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in Kymera Therapeutics during the 4th quarter valued at $344,000. GAMMA Investing LLC raised its stake in Kymera Therapeutics by 3,851.5% during the 1st quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after acquiring an additional 6,509 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Kymera Therapeutics by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock valued at $15,577,000 after acquiring an additional 20,346 shares in the last quarter. Finally, Millennium Management LLC raised its stake in Kymera Therapeutics by 205.0% during the 4th quarter. Millennium Management LLC now owns 115,918 shares of the company's stock valued at $4,663,000 after acquiring an additional 77,912 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.